Gary Kurtzman, Md

Prenosis is transforming clinical diagnosis with artificial intelligence that leverages holistic molecular and clinical data.

Sonobi is an independent, consumer-focused technology company that provides a fair and equitable media marketplace to connect advertisers directly with individuals. Sonobi’s JetStream technology is transforming the business of traditional impression-based advertising to individual-based advertising. By unifying premium media properties and Fortune 500 advertisers, Sonobi’s JetStream platform enables publishers and marketers to directly collaborate in order to create and deliver superior addressable communication plans for the people who matter most — consumers. With over a decade of innovation, Sonobi leads the way in CTV and OTT advertising, offering CTV Supply Optimization for increased conversions, revenue, and site visits. Our Performance Platform enables outcome-based advertising, boosting reach, lift, and ROAS, all while making TV advertising easy, affordable, and intuitive. We provide fast, flexible, and customizable solutions, ensuring direct access to the evolving world of advertising. For more information, please visit www.sonobi.com.

For too long, healthcare has settled for the status quo. We thought there had to be a better way. So we’re doing it. Consumers, empowered by technology, demand more from all of their experiences, including healthcare. So Zipnosis created device-agnostic virtual care that offers patients greater choice and convenience, offers providers improved efficiency, and still boosts the bottom line for health organizations. We use top clinical data plus technology that’s built around the people who use it to create better healthcare experiences. That means less wasted time, energy and resources. That means face-to-face help when it’s needed, and virtual solutions when it’s not. At Zipnosis, we are a team of unconventional thinkers—experts in clinical care, regulatory changes, technology, marketing—who are heralding change in an industry that is badly in need of disruption. We are the change healthcare needs. Join us.

Moxe empowers smarter, simpler, more secure data exchange for better healthcare. Working with EHRs, health systems, and payers, Moxe improves collaboration by digitizing release of information and enabling bi-directional data exchange. Moxe’s API-first approach is revolutionizing the secure exchange of clinical information, putting actionable insights directly into the clinical workflow. Moxe solutions help optimize risk adjustment, quality improvement, payment integrity, care management, and more.

Velano Vascular is transforming the inpatient experience with the PIVO™, a breakthrough needle-free blood collection device. PIVO aims to reduce painful needle sticks for inpatients, to improve practitioner safety, and to provide hospitals with a smarter financial solution for vascular access. Velano is backed by leading U.S. health systems including Sutter Health, Griffin Hospital and The Children's Hospital of Philadelphia, as well as First Round Capital, Kapor Capital, White Owl Capital, Safeguard Scientifics and dozens of heath industry veterans. Velano collaborates with innovators in patient-centered care, including Planetree, Intermountain Healthcare, Brigham & Women's Hospital and more. Our mission is to establish a new, more humane standard of care. We're looking for bright, tenacious candidates to join our incredible team of business and healthcare professionals. Check out our careers page here: http://velanovascular.com/careers/

PREDICT » PERSONALIZE » PERFORM. meQ partners with global enterprises as the intelligence engine that connects human potential to business performance. Our workforce intelligence platform predicts workforce risk with real‑time, AI‑driven analytics. We personalize resilience development at scale. We drive performance by linking workforce health to business outcomes. Enterprises that operationalize workforce resilience win on talent retention and engagement, manager and team effectiveness, and data‑driven decision making. Forget wellness apps or one‑off programs. Workforce intelligence is the new performance strategy. meQ is available in 17 languages and serves global enterprises in over 130 countries. Learn more at www.meQuilibrium.com.

Propeller Health is a precision digital health company on a mission to uplift every person living with chronic disease so they can take control of their health and live a better life. We power motivating, care-connected patient journeys and unify value for all stakeholders – providers, payers, pharma, and other healthcare and life sciences organizations. The Propeller Platform includes FDA-cleared and CE-marked medical devices, consumer apps, support and coaching, and secure access to clinical data for provider monitoring. Our precision approach is designed to motivate behavior change and track patient adherence with the goals of enabling medication optimization and helping predict costly exacerbations. In more than 150 peer-reviewed abstracts and publications, our digital-first chronic respiratory care platform has demonstrated improved quality of life and clinical outcomes while lowering healthcare costs. As a wholly owned subsidiary of ResMed, Propeller brings broad respiratory care expertise, digital therapeutic coverage, and scale globally.

Every day, our registered network of over 225,000 physicians (about 1 in 3 nationwide) visits the award-winning web and mobile community QuantiaMD to learn from top experts, seek advice, and collaborate on a wide range of topics. Our unique blend of expert content, social networking, and game mechanics creates an environment physicians want to explore and serves up high quality, meaningful interactions that inspire behavior change.

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion’s product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company’s lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company’s lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates.

Good Start Genetics is dedicated to helping grow healthy families through its best-in-class genetics offerings. Using advanced clinical sequencing, proprietary methods and information tailored to the individual, the Company's suite of offerings arms clinicians and patients with insightful and actionable information to promote successful pregnancies and help build healthy families. The Company’s product portfolio, including GeneVu, EmbryVu and VeriYou, encompasses a multifaceted approach to genetic testing, featuring solutions for both preimplantation and carrier screening, while offering comprehensive and flexible testing options helping a wider range of couples find their paths to pregnancy at significantly lower costs. Good Start Genetics complements these offerings with world class customer care and genetic counseling to help families stay well-informed and be better prepared for tomorrow. For more information, please visit www.goodstartgenetics.com or join us on Facebook, Twitter and LinkedIn.

At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.

Our mission is to offer in depth guidance and support to founders, teams, boards, and investors empowering them to navigate the complexities of their work and achieve ambitious, transformative goals for their organizations, their customers, and themselves.

route is building the "Waze" to mental health. route is a digital navigator for mental health, much like a Waze guiding individuals to find their most efficient “route” to emotional wellness. route is designed to provide authentic, empathetic, and personalized support to users as they navigate their emotions and mental health challenges. Leveraging technology as a tool for empowerment, route helps individuals build resilience and find emotional balance as they progress on their mental health journey.

Prenosis is transforming clinical diagnosis with artificial intelligence that leverages holistic molecular and clinical data.

Chasm Partners is a retained executive search firm and talent development organization that specializes in healthcare services, healthcare technology, and Life Sciences. We work with the nation’s most prominent, innovative, and growth-oriented companies focused on disrupting healthcare and help them achieve scale through human capital. Our clients are backed by top Venture Capital and Private Equity firms focused on addressing the most pressing challenges and opportunities facing healthcare today. Chasm Partners is proud to offer three core services: ChasmSearch executive recruiting, ChasmTeam recruitment process outsourcing, and ChasmLead executive coaching. Using our highly experienced team of recruiters, our ChasmSearch team places talented executives, VP-level and above, into the most critical leadership roles in healthcare. Each placement is guaranteed Onboarding Coaching through ChasmLead, which includes psychometric assessments and support in the executive’s new role, as well as organizational support and advisory services to the Client, if requested. In addition to executive search and coaching, ChasmTeam, a division of Chasm Partners, provides outsourced recruiting services to help high growth companies scale their workforce quickly across all levels and job functions. Like our clients, we are also growing rapidly; and we, too, are innovative when it comes to how we work. If you are an operator or experienced recruiter with similar values and excited about working in an entrepreneurial environment, we would love to talk with you.

Safeguard Scientifics (NYSE:SFE) provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media. Safeguard targets companies that are capitalizing on the next wave of enabling technologies with a particular focus on the Internet of Everything, enhanced security and artificial intelligence, which includes predictive analytics and machine learning. Safeguard typically deploys between $5 million and $25 million over the course of its partnership with a company, initially investing in a Series A or B Round and opportunistically in a Seed Round. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades.